Tags

Type your tag names separated by a space and hit enter

Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health.
Nutr Metab Cardiovasc Dis. 2018 11; 28(11):1155-1165.NM

Abstract

BACKGROUND AND AIMS

The receptor for advanced glycation end products (RAGE) is implicated in obesogenesis. Conversely, soluble RAGE (sRAGE) competitively inhibits RAGE. Our aim was to determine the effects of weight-loss via alternate day fasting (ADF) on sRAGE isoforms and evaluate potential relationships with body composition.

METHODS AND RESULTS

42 obese participants were randomized to control (CON) or ADF. For 24 weeks, the ADF group consumed 25% or 125% of their caloric requirements on alternating days while the CON group did not change their diet. Body fat was measured via DXA, visceral fat (VAT) via MRI and subcutaneous fat (SAT) was derived by subtracting VAT from total fat. sRAGE isoforms were measured via ELISAs. After 24 weeks, ADF -6.8 (-9.5, -3.5)kg (Median, IQR) lost more weight than CON -0.3 (-1.9, 1.0)kg (p < 0.05). The change in endogenous secretory RAGE (esRAGE) was different between ADF 15 (-30, 78)pg/mL and CON -21 (-72, 16)pg/mL after 24 weeks (p < 0.05). To examine the effect of changes in body composition, the cohort was stratified by median weight-, fat-, SAT-, and VAT-loss. The changes in all sRAGE isoforms were different between those above and below median weight-loss (p < 0.05) with sRAGE isoforms tending to decrease in individuals below the median. Changes in total sRAGE and esRAGE were different between individuals above compared to below median fat- and SAT-loss (p < 0.05). Those above median fat-loss increased esRAGE by 29 (-5, 66)pg/mL (p < 0.05).

CONCLUSION

Improvements in body composition are related to increased sRAGE isoforms, implicating sRAGE as a potential target for the treatment of obesity.

CLINICAL TRIAL REGISTRATION

NCT00960505.

Authors+Show Affiliations

School of Kinesiology, University of Michigan, Ann Arbor, MI, United States.Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, United States.School of Kinesiology, University of Michigan, Ann Arbor, MI, United States.Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, IN, United States.Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, United States.Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, United States.School of Kinesiology, University of Michigan, Ann Arbor, MI, United States. Electronic address: jmhaus@umich.edu.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

30297199

Citation

Miranda, E R., et al. "Endogenous Secretory RAGE Increases With Improvements in Body Composition and Is Associated With Markers of Adipocyte Health." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 28, no. 11, 2018, pp. 1155-1165.
Miranda ER, Fuller KNZ, Perkins RK, et al. Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health. Nutr Metab Cardiovasc Dis. 2018;28(11):1155-1165.
Miranda, E. R., Fuller, K. N. Z., Perkins, R. K., Kroeger, C. M., Trepanowski, J. F., Varady, K. A., & Haus, J. M. (2018). Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 28(11), 1155-1165. https://doi.org/10.1016/j.numecd.2018.07.009
Miranda ER, et al. Endogenous Secretory RAGE Increases With Improvements in Body Composition and Is Associated With Markers of Adipocyte Health. Nutr Metab Cardiovasc Dis. 2018;28(11):1155-1165. PubMed PMID: 30297199.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endogenous secretory RAGE increases with improvements in body composition and is associated with markers of adipocyte health. AU - Miranda,E R, AU - Fuller,K N Z, AU - Perkins,R K, AU - Kroeger,C M, AU - Trepanowski,J F, AU - Varady,K A, AU - Haus,J M, Y1 - 2018/08/02/ PY - 2018/03/24/received PY - 2018/07/23/revised PY - 2018/07/24/accepted PY - 2018/10/10/pubmed PY - 2019/4/4/medline PY - 2018/10/10/entrez KW - Adipokines KW - Alternate day fasting KW - Inflammation KW - Obesity KW - Soluble RAGE SP - 1155 EP - 1165 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 28 IS - 11 N2 - BACKGROUND AND AIMS: The receptor for advanced glycation end products (RAGE) is implicated in obesogenesis. Conversely, soluble RAGE (sRAGE) competitively inhibits RAGE. Our aim was to determine the effects of weight-loss via alternate day fasting (ADF) on sRAGE isoforms and evaluate potential relationships with body composition. METHODS AND RESULTS: 42 obese participants were randomized to control (CON) or ADF. For 24 weeks, the ADF group consumed 25% or 125% of their caloric requirements on alternating days while the CON group did not change their diet. Body fat was measured via DXA, visceral fat (VAT) via MRI and subcutaneous fat (SAT) was derived by subtracting VAT from total fat. sRAGE isoforms were measured via ELISAs. After 24 weeks, ADF -6.8 (-9.5, -3.5)kg (Median, IQR) lost more weight than CON -0.3 (-1.9, 1.0)kg (p < 0.05). The change in endogenous secretory RAGE (esRAGE) was different between ADF 15 (-30, 78)pg/mL and CON -21 (-72, 16)pg/mL after 24 weeks (p < 0.05). To examine the effect of changes in body composition, the cohort was stratified by median weight-, fat-, SAT-, and VAT-loss. The changes in all sRAGE isoforms were different between those above and below median weight-loss (p < 0.05) with sRAGE isoforms tending to decrease in individuals below the median. Changes in total sRAGE and esRAGE were different between individuals above compared to below median fat- and SAT-loss (p < 0.05). Those above median fat-loss increased esRAGE by 29 (-5, 66)pg/mL (p < 0.05). CONCLUSION: Improvements in body composition are related to increased sRAGE isoforms, implicating sRAGE as a potential target for the treatment of obesity. CLINICAL TRIAL REGISTRATION: NCT00960505. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/30297199/Endogenous_secretory_RAGE_increases_with_improvements_in_body_composition_and_is_associated_with_markers_of_adipocyte_health_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(18)30246-1 DB - PRIME DP - Unbound Medicine ER -